

GENLISA™ SARS-CoV-2 (Covid-19) Beta Neutralizing Antibody (B.1.351, B.1.351.2, B.1.351.3) ELISA

REF : KBVH420

Ver1.2

RUO

Enzyme Immunoassay for the Qualitative and Quantitative Detection of all types of Neutralizing Antibodies against SARS-CoV-2 (Variant B.1.351, B.1.351.2, B.1.351.3) in a species- and isotype-independent manner in serum or plasma.

RUO	For Research Use Only	REF	Catalog Number
	Store At	LOT	Batch Code
	Manufactured By		Biological Risk
	Expiry Date		Consult Operating Instructions

For Research Use Only. Purchase does not include or carry the right to resell or transfer this product either as a stand-alone product or as a component of another product. Any use of this product other than the permitted use without the express written authorization of KRISHGEN BioSystems is strictly prohibited.

REF KBVH420

 96 tests

KRISHGEN BioSystems For US/Europe Customers: toll free +1(888)-970-0827 | tel +1(562)-568-5005
For Asia/India Customers: tel +91(22)-49198700
Email: sales1@krishgen.com | <http://www.krishgen.com>

Introduction:

The GENLISA™ ELISA kits are used for assessing the specific biomarker in samples analytes which may be serum, plasma and cell culture supernatant as validated with the kit. The kit employs a blocking ELISA technique which mimics the virus neutralization process.

SARS-CoV-2-neutralizing antibodies primarily target the trimeric spike (S) glycoproteins on the viral surface that mediate entry into host cells. The S protein has two functional subunits that mediate cell attachment (the S1 subunit, existing of four core domains S1A through S1D) and fusion of the viral and cellular membrane (the S2 subunit).

Potent neutralizing antibodies often target the receptor interaction site in S1, disabling receptor interactions. The spike proteins of SARS-CoV-2 commonly bind to the human angiotensin converting enzyme 2 (ACE2) protein as a host receptor through their S1B domain. Receptor interaction is known to trigger irreversible conformational changes in coronavirus spike proteins enabling membrane fusion.

SARS-CoV-2 initiates an immune response, which leads to the production of antibodies. These neutralizing antibodies provide protection against future infection from SARS-CoV-2 (Variant B.1.351), as they remain in the circulatory system for months to years post infection.

SARS-CoV-2 keeps evolving by continual mutation which enable the virus to evade vaccines and immune systems. Some of the mutations ,the U.K. variant B.1.1.7, the Brazil variant P.1, the South Africa variant B.1.351 and the Indian variant B.1.617, may have allowed the virus to escape from neutralizing antibodies.

The combination of K417N, E484K, and N501Y substitutions is present in B.1.351 (Beta) which was first reported in South Africa.

This Neutralizing Kit works on using Recombinant SARS-CoV-2 (2019-nCoV) Spike RBD (K417N, E484K, N501Y) Protein and a Neutralizing Antibody sensitive to the variant as a Standard/Calibrator to measure the effective inhibition %.

Intended Use:


The GENLISA™ SARS-CoV-2 (Covid-19) Beta Neutralizing Antibody (B.1.351, B.1.351.2,B.1.351.3) ELISA kit is used as an analytical tool for the qualitative and quantitative detection all types of neutralizing antibodies against SARS-CoV-2 RBD (K417N, E484K, N501Y) in serum or plasma.

Principle:

The method employs sandwich ELISA technique. The protein-protein interaction between HRP-RBD and hACE2 can be blocked by neutralizing antibodies against SARS-CoV-2 RBD (K417N, E484K, N501Y).

Samples and controls are pipetted in a blank microtitre plate and incubated with HRP conjugated human SARS-CoV-2 RBD (K417N, E484K, N501Y) protein. The antibodies to SARS-CoV-2 (K417N, E484K, N501Y) present in the samples and controls bind to the SARS-CoV-2 RBD (K417N, E484K, N501Y) protein to form a complex.

This solution of bound and unbound antibodies to SARS-CoV-2 Variant B.1.351 (Beta) is then pipetted into human ACE2 coated microplate. After washing to remove the bound complex of Anti-SARS-CoV-2 Variant B.1.351, B.1.351.2, B.1.351.3 (Beta) and HRP conjugated SARS-CoV-2 RBD (K417N, E484K, N501Y), the substrate solution (TMB) is added to the microwells. Post incubation, color develops proportionally to the amount of unbound Anti-SARS-CoV-2 (Covid-19) Variant B.1.351, B.1.351.2, B.1.351.3 (Beta) present in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.



Materials Provided:

Part	Description	Qty
Human ACE-2 Coated Microtiter Plate	96 well polystyrene microplate (12 strips of 8 wells) coated with Human ACE2 protein	1 x 96 wells
Blank Microtiter Plate	96 well polystyrene uncoated microplate (12 strips of 8 wells)	1 x 96 wells
Anti-Human SARS-CoV-2 (sensitized to Beta Variant B.1.351, B.1.351.2, B.1.351.3) Standard	Lyophilized Anti-Human SARS-CoV-2 (sensitized to Beta Variant B.1.351, B.1.351.2, B.1.351.3) Standard concentrated - 2500 ng/ml	2 vials
SARS-CoV-2 RBD (K417N, E484K, N501Y):HRP Conjugate	SARS-CoV-2 RBD (K417N, E484K, N501Y): HRP Conjugate prepared in buffer with protein stabilizer and preservatives 0.02% methylisothiazolone and 0.02% bromonitrodioxane.	12 ml
(1X) Sample Diluent	Buffered protein base with preservative thiomersol < 0.01%	2 x 50 ml
(1X) Standard Diluent	Buffered protein base with preservative thiomersol < 0.01% with 1:1000 dilution human serum	10 ml
(20X) Wash Buffer	20-fold concentrated solution of buffered surfactant with preservative thiomersol < 0.01%. May turn yellow over time.	25 ml
TMB Substrate	Stabilized Chromogen	12 ml
Stop Solution	0.73M Phosphoric Acid	12 ml
Instruction Manual		1 no

*note: the Anti-Human SARS-CoV-2 Standard is to be used as Positive Control when running a qualitative assay by preparing it as the highest standard of 2000 ng/ml and prepared accordingly when running a qualitative assay.

Materials to be provided by the End-User:

1. Microtiter Plate Reader able to measure absorbance at 450 nm.
2. Adjustable pipettes and multichannel pipettor to measure volumes ranging from 25 ul to 1000 ul
3. Deionized (DI) water
4. Wash bottle or automated microplate washer
5. Graph paper or software for data analysis
6. Timer
7. Absorbent Paper

Handling/Storage:

1. Store main kit components at recommend temperature indicated on the component label.

2. Before using, bring all components to room temperature (18-25°C). Upon assay completion return all components to appropriate storage conditions.
3. The Substrate is light-sensitive and should be protected from direct sunlight or UV sources.

Health Hazard Warnings:

Reagents that contain preservatives may be harmful if ingested, inhaled or absorbed through the skin.



Sample Preparation and Storage:

Specimens should be clear and non-hemolyzed. Samples should be run at a number of dilutions to ensure accurate quantitation.

Blood is taken by venipuncture. Serum is separated after clotting by centrifugation. Plasma can be used, too. Lipaemic, hemolytic or contaminated samples should not be run. Repeated freezing and thawing should be avoided.

Samples should be diluted 1:1000 (v/v) for optimal recovery, (for example 1 ul sample + 999 ul sample diluent) prior to assay. In cases where matrix interferences is under or over observed, the samples may be diluted less or more respectively with Sample Diluent accordingly.

The samples may be kept at 2 - 8°C for up to three days. For long-term storage please store at -20°C.

Note: *Grossly hemolyzed samples are not suitable for use in this assay.*

Preparation before Use:

Allow serum or plasma samples to reach room temperature prior to assay. Take care to agitate patient samples gently in order to ensure homogeneity.

In cases where matrix interferences is under or over observed, the samples may be diluted with Sample Diluent accordingly.

The samples may be kept at 2 - 8°C for up to three days. For long-term storage please store at -20°C.

Note: *Grossly hemolyzed samples are not suitable for use in this assay.*

Reagent Preparation (all reagents should be diluted immediately prior to use):

1. Label any aliquots made with the kit Lot No and Expiration date and store it at appropriate conditions mentioned.
2. Bring all reagents to Room temperature before use.
3. **Reconstitute the lyophilized standard in 1ml Standard Diluent to get a concentration of 2500 ng/ml**
4. To make **Wash Buffer (1X)**; dilute **25 ml of 20X Wash Buffer** in **475 ml of DI water**.

For Quantitative Assay, dilute the concentrated Standard provided as under -

Standards Preparation: Perform serial dilutions by using reconstituted main stock standard solution as per the below table. Thus the Anti-SARS-CoV-2 (spike antibody) Standards concentration is 2000 ng/ml, 1000 ng/ml, 500 ng/ml, 250 ng/ml, 125 ng/ml, 62.5 ng/ml, 31.25 ng/ml, 15.625 ng/ml and 0 ng/ml. Sample Diluent serves as the zero standard (0 ng/ml).

Standard Concentration	Standard No	Dilution Particulars
2500 ng/ml	Original Standard	Standard (lyophilized), reconstituted with 1 ml Standard Diluent
2000 ng/ml	Standard No.9	400 ul Original Standard + 100 ul Standard Diluent (1X)
1000 ng/ml	Standard No.8	250 ul Standard No. 9 + 250 ul Standard Diluent (1X)
500 ng/ml	Standard No.7	250 ul Standard No. 8 + 250 ul Standard Diluent (1X)
250 ng/ml	Standard No.6	250 ul Standard No. 7 + 250 ul Standard Diluent (1X)
125 ng/ml	Standard No.5	250 ul Standard No. 6 + 250 ul Standard Diluent (1X)
62.5 ng/ml	Standard No.4	250 ul Standard No. 5 + 250 ul Standard Diluent (1X)
31.25 ng/ml	Standard No.3	250 ul Standard No. 4 + 250 ul Standard Diluent (1X)
15.625 ng/ml	Standard No.2	250 ul Standard No. 3 + 250 ul Standard Diluent (1X)
0 ng/ml	Standard No.1	500 ul Standard Diluent (1X)

**note: the Anti-Human SARS-CoV-2 Standard is to be used as Positive Control when running a qualitative assay by preparing it as the highest standard of 2000 ng/ml and Standard Diluent as the Negative Control.*

Procedural Notes:

1. In order to achieve good assay reproducibility and sensitivity, proper washing of the plates to remove excess un-reacted reagents is essential.
2. Avoid assay of Samples containing sodium azide (NaN₃), as it could destroy the HRP activity resulting in under-estimation of the amount of Anti-Human SARS-CoV-2 (Covid-19).
3. It is recommended that the Standards and Samples be assayed in duplicates.
4. Maintain a repetitive timing sequence from well to well for all the steps to ensure that the incubation timings are same for each well.
5. If the Substrate has a distinct blue color prior to use it may have been contaminated and use of such substrate can lead to compromisation of the sensitivity of the assay.
6. The plates should be read within 30 minutes after adding the Stop Solution.
7. Make a work list in order to identify the location of Standards and Samples.

Assay Procedure:

A) Neutralization Reaction

1. Pipette **100 ul** of **Negative Control (marked as Standard '1')** in duplicate to the respective wells in the blank microplate.
2. Pipette **100 ul** of **Positive Control** or freshly prepared **Standards** (for quantitative assay) in duplicate to the respective wells in the blank microplate.
3. Pipette **100 ul** of the diluted **Samples solution** into the respective wells in the blank microplate.
4. Add **100 ul** of **SARS-CoV-2 RBD:HRP Conjugate** into all the wells.
5. Seal the plate and **incubate** for **60 minutes** at **Room Temperature (18-25°C)**.

B) Binding Reaction

1. Pipette **100 ul** of **Negative Control solution** into the respective wells of the human ACE-2 coated microplate from the neutralization reaction plate.
2. Pipette **100 ul** of the **Positive Control solution** or freshly prepared **Standards solution** (for quantitative assay) into the respective wells of the human ACE-2 coated microplate from the neutralization reaction plate.
3. Pipette **100 ul** of the diluted **Samples solution** into the respective wells of the human ACE-2 coated microplate from the neutralization reaction plate.

4. Seal plate and **incubate** for **90 minutes** at **Room Temperature (18-25°C)**.
5. Aspirate and wash plate 4 times with **Wash Buffer (1X)** and blot residual buffer by firmly tapping plate upside down on absorbent paper. Wipe of any liquid from the bottom outside of the microtiter wells as any residue can interfere in the reading step. All the washes should be performed similarly.
6. Pipette **100 ul** of **TMB Substrate solution**.
7. **Incubate** in the dark for **30 minutes** at **Room Temperature**.
8. Stop reaction by adding **100 ul** of **Stop Solution** to each well.
9. **Read Absorbance** at 450 nm within 30 minutes of stopping reaction.

Qualitative Interpretation:

Calculation for Cut Off Values -

Read the sample and negative/positive control wells on microtitre plate reader at 450nm.

The OD (Optical Density) of NC (Negative Control) in duplicate should be used for calculating the mean and standard deviation. This is the $Negative_{mean}$.

The Cut-Off for Negative Samples is equal to a value greater than $(Negative_{mean} - 2*Standard\ Deviation)$.

Formula:

Negative Sample Value = $OD > (Negative_{mean} - 2*SD)$

Typical example –

Sample Type	Absorbance #1	Absorbance #2	Mean
Negative	2.561	2.928	2.744

Therefore, Cut-Off = Mean - 2*SD
 = 2.744 - (2*0.260)
 = 2.744 - 0.519
 = 2.225

Interpretation of Results:

Positive Samples *	< Cut Off *
Negative Samples *	>= Cut Off *
Unequivocal/Grey Zone Samples *	<Cut Off - >(Cut Off-0.50)

* The cutoff value is based on validation using recombinant antibodies in the assay. Users may set up their own cutoff values based on different patient serum panels from different geographic locations or ethnic backgrounds.

Note:

1. If samples show false positive or false negative results; we recommend correlation with clinical interpretation.
2. If samples report unequivocal or grey zone absorbances, we recommend to re-test and report such samples as unequivocal samples, if clinical interpretation is not available.

Validity of the Test:

The use of controls allows validation of the test. The test is valid if the absorbance of Positive Control Value is lesser than 1.00. In case the control value is out of range, we recommend you to repeat the assay.

Quantitative Interpretation:

The Inhibition Rate of the Neutralizing Antibodies may also be measured. The user can determine the results of the sample by using the following formula:


$$\text{Inhibition} = 1 - \frac{\text{OD value of Sample}}{\text{OD value of Negative Control}} \times 100\%$$

In the quantitative assay, determine the mean absorbance for each set of duplicate standards and samples. Plot the standard curve on standard graph paper, with neutralizing antibody concentration on the x-axis and inhibition rate % on the y-axis. Draw the best fit straight line through the standard points. To determine the unknowns neutralizing antibody concentrations, find the unknowns inhibition rate % value on the y-axis and draw a horizontal line to the standard curve. At the point of intersection, draw a vertical line to the x-axis and read the neutralizing antibody concentration. Software which is able to generate a cubic spline curve-fit, 4-PL or a polynomial regression to the 3rd order is best recommended for automated results.

Typical Data
(not to be used for your assay interpretation).

Standard Concentration (ng/ml)	Mean Abs	% Inhibition
0	2.952	0.0
15.625	2.328	21.1
31.25	1.803	38.9
62.5	1.274	56.9
125	0.738	75.0
250	0.426	85.6
500	0.291	90.1
1000	0.204	93.1
2000	0.145	95.1

Typical Inhibition Graph



Limitation of the Procedure:

This ELISA test is designed for qualitative and/or quantitative detection of the neutralizing antibodies to SARS- CoV-2 only.

Performance Characteristics:

Specificity of the Neutralizing Antibody (Standard), provided in the Kit:

The standard antibody used in the kit has cross-reactivity in ELISA with SARS-CoV-2 (2019-nCoV) Spike RBD Protein. It has no cross-reactivity in ELISA with SARS-CoV Spike S1-mFc Protein, SARS-CoV Spike RBD-His Protein, MERS-CoV Spike S1 Protein, HCoV-HKU1 (isolate N1) Spike S1 Protein, HCoV-HKU1 (isolate N5) Spike S1 Protein, HCoV-NL63 Spike S1 Protein, HCoV-229E Spike S1 Protein, HCoV-OC43 Spike S1+S2 ECD Protein.

The Neutralizing antibody was also tested against the following variants and specificity to the same was graded in terms of low, medium and high based on the neutralizing capacity. The Neutralizing antibody has medium neutralizing capacity against WT, B.1.1.7, B.1.351, P.1, B.1.617 variants of spike RBD.

Microneutralization (MN):

The standard (SARS-CoV-2 neutralizing antibody) used in the kit was tested for neutralization. The neutralization activity is measured by microneutralization assay in vitro.

The virus microneutralization (MN) test was performed on 293T-ACE2 cells infected with SARS-CoV-2 (2019-nCoV) Spike Pseudovirus under treatment of serial dilutions of neutralizing antibody. The infection was neutralized by increasing concentrations of Anti-SARS-CoV-2 Neutralizing Antibody. The rate of inhibition was determined by comparing the Relative Light Unit (RLU) of Luciferase reporter in different antibody concentrations.

Characteristics of the spike RBD Protein (used as conjugated to HRP):

The SARS-CoV-2 (2019-nCoV) Spike RBD (K417N, E484K, N501Y) Protein was expressed in HEK293 cells using a DNA sequence encoding the Spike RBD (YP_009724390.1, with mutations K417N, E484K, N501Y) (Arg319-Phe541). The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.351) which emerged in the South Africa.

Safety Precautions:

- **This kit is For Research Use Only.** Follow the working instructions carefully.
- The expiration dates stated on the kit are to be observed. The same relates to the stability stated for reagents
- Do not use or mix reagents from different lots.
- Do not use reagents from other manufacturers.
- Avoid time shift during pipetting of reagents.
- All reagents should be kept in the original shipping container.
- Some of the reagents contain small amount of sodium azide (< 0.1 % w/w) as preservative. They must not be swallowed or allowed to come into contact with skin or mucosa.
- Source materials maybe derived from human body fluids or organs used in the preparation of this kit were tested and found negative for HBsAg and HIV as well as for HCV antibodies. However, no known test guarantees the absence of such viral agents. Therefore, handle all components and all patient samples as if potentially hazardous.
- Since the kit contains potentially hazardous materials, the following precautions should be observed
 - Do not smoke, eat or drink while handling kit material
 - Always use protective gloves
 - Never pipette material by mouth
 - Wipe up spills promptly, washing the affected surface thoroughly with a decontaminant.
- In any case GLP should be applied with all general and individual regulations to the use of this kit.



References:

Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses
S Jiang, C Hillyer, L Du - Trends in immunology, 2020 - Elsevier

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein
AC Walls, YJ Park, MA Tortorici, A Wall, AT McGuire... - Cell, 2020 - Elsevier

A human monoclonal antibody blocking SARS-CoV-2 infection
C Wang, W Li, D Drabek, NMA Okba... - Nature ..., 2020 - nature.com

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor
M Hoffmann, H Kleine-Weber, S Schroeder, N Krüger... - Cell, 2020 - Elsevier

Potent human neutralizing antibodies elicited by SARS-CoV-2 infection
B Ju, Q Zhang, X Ge, R Wang, J Yu, S Shan, B Zhou... - BioRxiv, 2020 - biorxiv.org

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
J Lan, J Ge, J Yu, S Shan, H Zhou, S Fan, Q Zhang... - Nature, 2020 - nature.com

A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV
M Yuan, NC Wu, X Zhu, CCD Lee, RTY So, H Lv... - ..., 2020 - science.sciencemag.org

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
X Ou, Y Liu, X Lei, P Li, D Mi, L Ren, L Guo... - Nature ..., 2020 - nature.com

Duration of serum neutralizing antibodies for SARS-CoV-2: lessons from SARS-CoV infection
Q Lin, L Zhu, Z Ni, H Meng, L You - Journal of Microbiology ..., 2020 - ncbi.nlm.nih.gov

LIMITED WARRANTY

Krishgen Biosystems does not warrant against damages or defects arising in shipping or handling, or out of accident or improper or abnormal use of the Products; against defects in products or components not manufactured by Krishgen Biosystems, or against damages resulting from such non-Krishgen Biosystems made products or components. Krishgen Biosystems passes on to customer the warranty it received (if any) from the maker thereof of such non Krishgen made products or components.

This warranty also does not apply to Products to which changes or modifications have been made or attempted by persons other than pursuant to written authorization by Krishgen Biosystems.

THIS WARRANTY IS EXCLUSIVE. The sole and exclusive obligation of Krishgen Biosystems shall be to repair or replace the defective Products in the manner and for the period provided above. Krishgen Biosystems shall not have any other obligation with respect to the Products or any part thereof, whether based on contract, tort, and strict liability or otherwise. Under no circumstances, whether based on this Limited Warranty or otherwise, shall Krishgen Biosystems be liable for incidental, special, or consequential damages.

This Limited Warranty states the entire obligation of Krishgen Biosystems with respect to the Products. If any part of this Limited Warranty is determined to be void or illegal, the remainder shall remain in full force and effect.

Krishgen Biosystems. 2024

THANK YOU FOR USING KRISHGEN PRODUCT!